West Pharmaceutical Services, Inc. · NYSE:WST
West Pharmaceutical Services — J.P. Morgan Healthcare Conference 2017
22 slides from West Pharmaceutical Services's conference presentation, Jan 11, 2017
Slide 1: J.P. Morgan Healthcare Conference
West Pharmaceutical Services, Inc. J.P. Morgan Healthcare Conference Eric M. Green, President & CEO January 11, 2017
Slide 2: Safe Harbor Statement
J.P. Morgan HC Conference 2 | Safe Harbor Statement Cautionary Statement Under the Private Securities Litigation Reform Act of 1995 This presentation and any accompanying management commentary contain “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Ac
Slide 3: Our Mission
Our Mission By your side… Pharmaceutical, biotechnology, generic and medical device companies trust West and our ability to deliver consistent high-quality and technologically advanced containment and delivery solutions. We share the commitment of our customers to improve the health of patients worl
Slide 4: A 90-Year History
A 90-Year History J.P. Morgan HC Conference 4 |
Slide 5: An Integral Part of the Healthcare Industry
An Integral Part of the Healthcare Industry Top 35 Injectable biologics rely on West and Daikyo components ~ 40 Billion Components manufactured annually Top 75 Supplier to the top 75 pharmaceutical & biotech injectable companies J.P. Morgan HC Conference 5 |
Slide 6: West's Role in Delivering Medicines to Patients
West’s Role in Delivering Medicines to Patients Proprietary Products Stoppers Seals Caps Syringe components Daikyo CZ vials & syringes Reconstitution systems Self-injection devices Contract-Manufactured Products Project management Engineering Injection molding Device assembly Advanced technologies $
Slide 7: West Business at a Glance
Net Sales* By Product Category Net Sales* By Geography Americas Europe, Middle East, Africa Asia Pacific 54% 39% 7% Net Sales* By Market Group High-Value Components Standard Packaging Delivery Devices Contract-Manufactured Products P R OPRI E T A R Y P R O D U C T S Pharma Generics Biologics Contrac
Slide 8: Long-term Strategy
Long-term Strategy Market Led and Exceptional Customer Experience Operational Effectiveness Product and Service Differentiation Drive Shareholder Value Become the world leader in integrated containment and delivery of injectable medicines J.P. Morgan HC Conference 8 |
Slide 9: Addressing Unique Customer Needs
Addressing Unique Customer Needs Quality – A High Bar Set By Our Customers GENERICS Speed to market Efficient manufacturing BIOLOGICS Packaging solutions for sensitive molecules Self-injection technologies PHARMA Total cost of ownership Life cycle management Quality manufacturing Design for manufact
Slide 10: Novel Injectable Approvals
Novel Injectable Approvals 2014 2015 2016 Biologics 18 25 14 Small Molecules (NMEs) 9 7 6 TOTAL 27 32 20 West Participation on Newly Approved Injectable Medicines West continues to increase its participation on newly approved injectable medicines Known West Participation 20 74% 24 75% 18 90% J.P. Mo
Slide 11: Differentiated Solutions: Standard Packaging—Stoppers & Seals
West solutions: Integrated containment & delivery Increasing levels of customer intimacy Increasing value to West STANDARD est Differentiated Solutions: Standard Packaging—Stoppers & Seals J.P. Morgan HC Conference 11 |
Slide 12: Differentiated Solutions: High-Value Components
West solutions: Integrated containment & delivery Increasing levels of customer intimacy Increasing value to West STANDARD est Differentiated Solutions: High-Value Components J.P. Morgan HC Conference 12 | STERILIZED WASHED COATED
Slide 13: Differentiated Solutions: Increasing Quality & Inspection
West solutions: Integrated containment & delivery Increasing levels of customer intimacy Increasing value to West STANDARD est Differentiated Solutions: Increasing Quality & Inspection J.P. Morgan HC Conference 13 | STERILIZED WASHED COATED CAMERA INSPECTED QUALITY BY DESIGN
Slide 14: Differentiated Solutions: Reconstitution & Self Injection Devices
West solutions: Integrated containment & delivery ADMINISTERED SELF INJECTION est Differentiated Solutions: Reconstitution & Self Injection Devices J.P. Morgan HC Conference 14 | Increasing levels of customer intimacy Increasing value to West CONTAINMENT
Slide 15: Contract Manufacturing: By the Numbers
Contract Manufacturing: By the Numbers 50 Years OF PROVIDING INNOVATIVE SOLUTIONS 8 Billion COMPONENTS MANUFACTURED ANNUALLY $302 Million IN NET SALES IN 2015 1 Million SQUARE FEET MANUFACTURING SPACE 1,600 EMPLOYEES ACROSS 8 MANUFACTURING FACILITIES AROUND THE WORLD J.P. Morgan HC Conference 15 |
Slide 16: Differentiated Solutions: Integrated Containment & Delivery
West solutions: Integrated containment & delivery STERILIZED WASHED COATED ADMINISTERED CAMERA INSPECTED QUALITY BY DESIGN CONTAINMENT SELF INJECTION INJECTION MOLDING MULTI-COMPONENT ASSEMBLY STANDARD est Differentiated Solutions: Integrated Containment & Delivery J.P. Morgan HC Conference 16 | Inc
Slide 17: Product Net Sales & Margin Growth
Circles reflect relative size of 2015 net sales Product Net Sales & Margin Growth 2011-2015 compound annual net sales growth rates (excludes currency) High-value components have driven growth Proprietary devices present significant growth opportunity Steady Contract Manufacturing and standard
Slide 18: Global Operations
Global Operations 40 billion Number of components manufactured annually 290 Annual customer audits 28 Manufacturing sites servicing our worldwide customer base < 0.1 Parts per million of out-of-spec parts J.P. Morgan HC Conference 18 |
Slide 19: 2016 Highlights
2016 Highlights Realigned to a market-led strategy, while continuing to grow the business to record levels Completed expansions in Kinston and Dublin to build capacity; on track with Waterford build Reduced lead times AND improved quality metrics Improved corporate-wide safety metrics and re
Slide 20: Sustained, Consistent Growth
0% 100% 200% 300% 400% 500% 2011 2012 2013 2014 2015 20162011 2012 2013 2014 2015 Net Sales Sustained, Consistent Growth 2011 2012 2013 2014 2015 Adjusted Diluted EPS* (Non-GAAP) Constant Currency CAGR 6.7%* Comparison of Cumulative Five-Year Total Return S&P MidCap 400 Index West Pharmaceutical Ser
Slide 21: Building for the Future
Building for the Future Global operations expanding capacity to meet growing customer demand Market-led strategy addressing the specific needs of pharmaceutical, biotechnology, generic and medical device customers Strong competitive position Quality culture Designed into regulated products Sci
Slide 22: Appendix: Reconciliation of Non-GAAP Measures
Appendix: Reconciliation of Non-GAAP Measures 2015 2014 2013 2012 2011 Diluted EPS Reported (GAAP) $1.30 $1.75 $1.57 $1.15 $1.08 Pension settlement charge 0.43 - - - - Executive retirement and related costs 0.09 - - - 0.03 License costs - 0.01 - - - Discrete tax items 0.01 0.02 0.06 0.03 0.02 Restru
West Pharmaceutical Services — J.P. Morgan Healthcare Conference 2017 on 6ix